Search

Displaying results 161 - 170 of 7090 in total

Target
Sodium-dependent dopamine transporter
go.drugbank.com/bio_entities/BE0000647
TargetTransporterHumans
Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- ...
Synonyms: DA transporter
Drug
Rilpivirine
go.drugbank.com/drugs/DB08864
ApprovedInvestigational
[A31328] It is a diarylpyrimidine derivative. … [A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.
Products: REKAMBYS® 300 MG/ML SUSPENSIÓN INYECTABLE DE LIBERACIÓN PROLONGADA
Drug
Nitrendipine
go.drugbank.com/drugs/DB01054
ApprovedWithdrawn
Nitrendipine is a calcium channel blocker with marked vasodilator action.
Products: NITRENDIPINO DE 10 MG, NITRENDIPINO DE 20 MG
Drug
Licorice
go.drugbank.com/drugs/DB10675
Approved
Licorice allergenic extract is used in allergenic testing.
Mixtures: Retinol Collagen Complex Day Night NeckProducts: Baekcho-DS
Drug
Raxtozinameran
go.drugbank.com/drugs/DB18228
ApprovedInvestigational
It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Synonyms: messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)Products: COMIRNATY® VACUNA DE ARNM CONTRA COVID-19
Drug
Coagulation factor VII human
go.drugbank.com/drugs/DB13150
ApprovedInvestigational
Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
Products: CONCENTRADO DE FACTOR VII
Drug
Clonidine
go.drugbank.com/drugs/DB00575
ApprovedInvestigational
[L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexProducts: Clonidine Transdermal System USP, 0.1 mg/day, Clonidine Transdermal System USP, 0.2 mg/day
Drug
Larotrectinib
go.drugbank.com/drugs/DB14723
ApprovedInvestigational
It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays
Products: VITRAKVI®CÁPSULAS DE 100MG
Drug
Edetate calcium disodium anhydrous
go.drugbank.com/drugs/DB14598
ApprovedInvestigational
[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774] … Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body.
Categories: Compounds used in a research, industrial, or household settingProducts: Calcium Edetate de Sodium
Drug
Paliperidone
go.drugbank.com/drugs/DB01267
ApprovedInvestigational
It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. … It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Categories: Dopamine D2 Receptor AntagonistsProducts: INVEGA SUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 25MG, INVEGASUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 75 MG